Return to Listing

1 result(s) for

PI Name Protocol # Title
Rebecca Silbermann STUDY00018117 A Phase 1/2a Open-label, Dose-Escalation Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Patients With Relapsed/Refractory Multiple Myeloma
 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080